NYSE - Nasdaq Real Time Price USD

Eli Lilly and Company (LLY)

Compare
859.88 -18.41 (-2.10%)
At close: 4:00 PM EDT
859.88 0.00 (0.00%)
After hours: 4:53 PM EDT
Loading Chart for LLY
DELL
  • Previous Close 878.29
  • Open 872.50
  • Bid 857.50 x 1100
  • Ask 859.33 x 1100
  • Day's Range 854.27 - 877.90
  • 52 Week Range 446.56 - 966.10
  • Volume 2,652,988
  • Avg. Volume 2,866,149
  • Market Cap (intraday) 774.24B
  • Beta (5Y Monthly) 0.41
  • PE Ratio (TTM) 127.20
  • EPS (TTM) 6.76
  • Earnings Date Aug 8, 2024
  • Forward Dividend & Yield 5.20 (0.59%)
  • Ex-Dividend Date Aug 15, 2024
  • 1y Target Est 917.64

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

www.lilly.com

43,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: LLY

View More

Related Videos: LLY

CrowdStrike outage, Biden, Fifth Third Bank CEO: Catalysts

Global IT outages caused by a CrowdStrike (CRWD) update to Microsoft Windows systems (MSFT) are rippling through major industries, causing massive issues from grounded planes to down 9-1-1 call centers. CrowdStrike management has addressed the outage as an incident related to an update, not a cyberattack. Although the CME FedWatch tool puts the probability of an interest rate cut at nearly 100% in September, there is still much uncertainty around ongoing geopolitical conflicts and the upcoming election in November. With so much that could happen in the second half of the year, investors are looking for strategies to solidify their positions. ProShares global investment strategist Simeon Hyman joined the show to break down some of the best strategies investors should consider heading into the second half of 2024. Shares of oil field services company Halliburton (HAL) fell after its second quarter revenue fell short of Street estimates. Its North America revenue declined 3% to $2.5 billion sequentially while international revenue rose 3% to $3.4 billion. Shares of Eli Lilly (LLY) are soaring after the pharmaceutical giant received regulatory approval in China for its GLP-1 weight-loss drug, Zepbound. Fifth Third Bancorp (FITB) recently posted its second quarter earnings, revealing total revenue of $2.08 billion, just below estimates of $2.12 billion. Net income available to common shareholders was $561 million, a 17% increase compared to the previous quarter. Fifth Third Bancorp CEO Tim Spence sits down with Yahoo Finance executive editor Brian Sozzi to discuss the regional bank's performance as well as how it is preparing for uncertainty related to the Federal Reserve's interest rate environment and the 2024 election. For more expert insight and the latest market action, click here. This post was written by Nicholas Jacobino

Performance Overview: LLY

Trailing total returns as of 7/24/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

LLY
48.02%
S&P 500
13.78%

1-Year Return

LLY
87.50%
S&P 500
19.64%

3-Year Return

LLY
264.12%
S&P 500
23.01%

5-Year Return

LLY
754.80%
S&P 500
80.58%

Compare To: LLY

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: LLY

View More

Valuation Measures

Annual
As of 7/23/2024
  • Market Cap

    790.82B

  • Enterprise Value

    814.44B

  • Trailing P/E

    129.35

  • Forward P/E

    64.10

  • PEG Ratio (5yr expected)

    1.42

  • Price/Sales (ttm)

    22.08

  • Price/Book (mrq)

    61.72

  • Enterprise Value/Revenue

    22.67

  • Enterprise Value/EBITDA

    84.06

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    17.08%

  • Return on Assets (ttm)

    12.60%

  • Return on Equity (ttm)

    50.75%

  • Revenue (ttm)

    35.93B

  • Net Income Avi to Common (ttm)

    6.14B

  • Diluted EPS (ttm)

    6.76

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.65B

  • Total Debt/Equity (mrq)

    204.28%

  • Levered Free Cash Flow (ttm)

    -1.23B

Research Analysis: LLY

View More

Earnings Per Share

Consensus EPS
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

600.00 Low
917.64 Average
859.88 Current
1,100.00 High
 

Company Insights: LLY

Research Reports: LLY

View More
  • Daily – Vickers Top Buyers & Sellers for 07/12/2024

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

     
  • Daily – Vickers Top Buyers & Sellers for 07/10/2024

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

     
  • Daily – Vickers Top Buyers & Sellers for 07/09/2024

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

     
  • Eli Lilly: Announced Morphic Acquisition Yields Potential New Blockbuster Inflammatory Bowel Drug

    Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

    Rating
    Price Target
     

People Also Watch